Magazine Article | July 1, 2020

Companies To Watch: Equillium

Source: Life Science Leader

By Wayne Koberstein, Executive Editor, Life Science Leader magazine
Follow Me On Twitter @WayneKoberstein

Keeping a close eye on the COVID-19 challenge but sticking to acute graft-versus-host disease, uncontrolled asthma, and lupus nephritis as primary inflammation targets

SNAPSHOT

Bruce Steel
Equillium is developing its lead candidate, itolizumab, for autoimmune/inflammatory maladies: acute graft-versus-host disease (aGVHD), uncontrolled asthma, and lupus nephritis. Itolizumab targets the CD6-ALCAM (activated leukocyte cell adhesion molecule) inflammatory pathway to block activation and trafficking of effector T (Teff) cells and restore their natural balance with regulatory T (Treg) cells. A Phase 1b/2 trial in aGVHD is in progress, but the company’s Phase 1b uncontrolled asthma trial and Phase 1b lupus nephritis trial have been paused because of difficulties in institutional settings related to the COVID-19 pandemic.

VIEW THE MAGAZINE ARTICLE!
Signing up provides unlimited access to:
Signing up provides unlimited access to:
  • Trend and Leadership Articles
  • Case Studies
  • Extensive Product Database
  • Premium Content
HELLO. PLEASE LOG IN. X

Not yet a member of Life Science Leader? Register today.

ACCOUNT SIGN UP X
Please fill in your account details
Login Information
I'm interested in newsletter subscriptions.
ACCOUNT SIGN UP

Subscriptions

Sign up for the newsletter that brings you the industry's latest news, technologies, trends and products.

You might also want to: